Identification of predictive factors for early relapse in patients with unresectable stage III non‐small cell lung cancer receiving consolidation durvalumab after concurrent chemoradiation therapy

Abstract Background Patients with locally advanced, unresectable, non‐small cell lung cancer (NSCLC) receiving definitive concurrent chemoradiation therapy (CCRT) benefit from durvalumab consolidation therapy. However, predictive factors for early relapse during durvalumab maintenance have not yet b...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Jung Hyun Nam, Chang Dong Yeo, Chan Kwon Park, Sung Kyoung Kim, Ju Sang Kim, Yong Hyun Kim, Jin Woo Kim, Seung Joon Kim, Sang Haak Lee, Hye Seon Kang
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Wiley 2023-09-01
Schriftenreihe:	Thoracic Cancer
Schlagworte:	chemoradiotherapy durvalumab non‐small cell lung cancer recurrence
Online-Zugang:	https://doi.org/10.1111/1759-7714.15050
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!